These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19196867)

  • 1. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies.
    Nahimana A; Attinger A; Aubry D; Greaney P; Ireson C; Thougaard AV; Tjørnelund J; Dawson KM; Dupuis M; Duchosal MA
    Blood; 2009 Apr; 113(14):3276-86. PubMed ID: 19196867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells.
    Cagnetta A; Caffa I; Acharya C; Soncini D; Acharya P; Adamia S; Pierri I; Bergamaschi M; Garuti A; Fraternali G; Mastracci L; Provenzani A; Zucal C; Damonte G; Salis A; Montecucco F; Patrone F; Ballestrero A; Bruzzone S; Gobbi M; Nencioni A; Cea M
    Clin Cancer Res; 2015 Sep; 21(17):3934-45. PubMed ID: 25964294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preclinical study on the rescue of normal tissue by nicotinic acid in high-dose treatment with APO866, a specific nicotinamide phosphoribosyltransferase inhibitor.
    Olesen UH; Thougaard AV; Jensen PB; Sehested M
    Mol Cancer Ther; 2010 Jun; 9(6):1609-17. PubMed ID: 20515945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicotinamide phosphoribosyltransferase inhibitor APO866 induces C6 glioblastoma cell death via autophagy.
    Yang P; Zhang L; Shi QJ; Lu YB; Wu M; Wei EQ; Zhang WP
    Pharmazie; 2015 Oct; 70(10):650-5. PubMed ID: 26601421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anti-lymphoma activity of APO866, an inhibitor of nicotinamide adenine dinucleotide biosynthesis, is potentialized when used in combination with anti-CD20 antibody.
    Nahimana A; Aubry D; Breton CS; Majjigapu SR; Sordat B; Vogel P; Duchosal MA
    Leuk Lymphoma; 2014 Sep; 55(9):2141-50. PubMed ID: 24283753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.
    Zhang LY; Liu LY; Qie LL; Ling KN; Xu LH; Wang F; Fang SH; Lu YB; Hu H; Wei EQ; Zhang WP
    Eur J Pharmacol; 2012 Jan; 674(2-3):163-70. PubMed ID: 22119381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAD⁺ depletion by APO866 in combination with radiation in a prostate cancer model, results from an in vitro and in vivo study.
    Zerp SF; Vens C; Floot B; Verheij M; van Triest B
    Radiother Oncol; 2014 Feb; 110(2):348-54. PubMed ID: 24412016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
    Venkateshaiah SU; Khan S; Ling W; Bam R; Li X; van Rhee F; Usmani S; Barlogie B; Epstein J; Yaccoby S
    Exp Hematol; 2013 Jun; 41(6):547-557.e2. PubMed ID: 23435312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells.
    Zoppoli G; Cea M; Soncini D; Fruscione F; Rudner J; Moran E; Caffa I; Bedognetti D; Motta G; Ghio R; Ferrando F; Ballestrero A; Parodi S; Belka C; Patrone F; Bruzzone S; Nencioni A
    Exp Hematol; 2010 Nov; 38(11):979-88. PubMed ID: 20696207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity.
    Yang HJ; Yen MC; Lin CC; Lin CM; Chen YL; Weng TY; Huang TT; Wu CL; Lai MD
    Exp Biol Med (Maywood); 2010 Jul; 235(7):869-76. PubMed ID: 20558841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critical role of autophagy in antileukemia/lymphoma effects of APO866, an inhibitor of NAD biosynthesis.
    Ginet V; Puyal J; Rummel C; Aubry D; Breton C; Cloux AJ; Majjigapu SR; Sordat B; Vogel P; Bruzzone S; Nencioni A; Duchosal MA; Nahimana A
    Autophagy; 2014 Apr; 10(4):603-17. PubMed ID: 24487122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenografts.
    Jensen MM; Erichsen KD; Johnbeck CB; Björkling F; Madsen J; Bzorek M; Jensen PB; Højgaard L; Sehested M; Kjær A
    PLoS One; 2013; 8(1):e53410. PubMed ID: 23308217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting NAD immunometabolism limits severe graft-versus-host disease and has potent antileukemic activity.
    Gerner RR; Macheiner S; Reider S; Siegmund K; Grabherr F; Mayr L; Texler B; Moser P; Effenberger M; Schwaighofer H; Moschen AR; Kircher B; Oberacher H; Zeiser R; Tilg H; Nachbaur D
    Leukemia; 2020 Jul; 34(7):1885-1897. PubMed ID: 31974433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis.
    Korotchkina L; Kazyulkin D; Komarov PG; Polinsky A; Andrianova EL; Joshi S; Gupta M; Vujcic S; Kononov E; Toshkov I; Tian Y; Krasnov P; Chernov MV; Veith J; Antoch MP; Middlemiss S; Somers K; Lock RB; Norris MD; Henderson MJ; Haber M; Chernova OB; Gudkov AV
    Leukemia; 2020 Jul; 34(7):1828-1839. PubMed ID: 31896781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.
    Grozio A; Sociali G; Sturla L; Caffa I; Soncini D; Salis A; Raffaelli N; De Flora A; Nencioni A; Bruzzone S
    J Biol Chem; 2013 Sep; 288(36):25938-25949. PubMed ID: 23880765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of leukocyte infiltration and cartilage degradation by selective inhibition of pre-B cell colony-enhancing factor/visfatin/nicotinamide phosphoribosyltransferase: Apo866-mediated therapy in human fibroblasts and murine collagen-induced arthritis.
    Evans L; Williams AS; Hayes AJ; Jones SA; Nowell M
    Arthritis Rheum; 2011 Jul; 63(7):1866-77. PubMed ID: 21400478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
    Cea M; Cagnetta A; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Roccaro A; Sacco A; Calimeri T; Cottini F; Jakubikova J; Kong SY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
    Blood; 2012 Oct; 120(17):3519-29. PubMed ID: 22955917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia.
    Mitchell SR; Larkin K; Grieselhuber NR; Lai TH; Cannon M; Orwick S; Sharma P; Asemelash Y; Zhang P; Goettl VM; Beaver L; Mims A; Puduvalli VK; Blachly JS; Lehman A; Harrington B; Henderson S; Breitbach JT; Williams KE; Dong S; Baloglu E; Senapedis W; Kirschner K; Sampath D; Lapalombella R; Byrd JC
    Blood Adv; 2019 Feb; 3(3):242-255. PubMed ID: 30692102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
    Pogrebniak A; Schemainda I; Azzam K; Pelka-Fleischer R; Nüssler V; Hasmann M
    Eur J Med Res; 2006 Aug; 11(8):313-21. PubMed ID: 17052966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the vulnerability to NAD
    Takao S; Chien W; Madan V; Lin DC; Ding LW; Sun QY; Mayakonda A; Sudo M; Xu L; Chen Y; Jiang YY; Gery S; Lill M; Park E; Senapedis W; Baloglu E; Müschen M; Koeffler HP
    Leukemia; 2018 Mar; 32(3):616-625. PubMed ID: 28904384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.